Studies of tau biomarkers have shown a recent increase in interest for a few reasons: failure of clinical trials of anti-amyloid therapies, a more significant correlation between tauopathy and AD progression (unlike amyloid pathology), recent studies suggesting pathways of tauopathy progression independent of amyloid pathology and the diagnosis of primary tauopathies46-.49 This evidence concerns the gene MAPT and tauopathy.